Vistagen therapeutics stock.
H Snodgrass VTGN stock SEC Form 4 insiders trading. H has made over 3 trades of the VistaGen Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 3,750 units of VTGN stock worth $10,238 on 17 August 2021.. The largest trade he's ever made was buying 15,000 units of VistaGen …
Summary of all time highs, changes and price drops for Vistagen Therapeutics; Historical stock prices; Current Share Price: US$3.65: 52 Week High: …Find the latest Vistagen Therapeutics, Inc. (VTGN) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C., that further supporting ...Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.
Aug 14, 2023 · Vistagen to Present at Stifel 2023 Healthcare Conference Nov 08, 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 8, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders ... William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on …
Aug 7, 2023 · Vistagen Therapeutics (NASDAQ: VTGN) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer has been struggling all year, dipping into ...
If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in recent years is crafting and building.VTGN has an Altman Z-Score of -5.47 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for VistaGen Therapeutics, Inc. (VTGN) stock, including valuation metrics, financial numbers, share information and more.7.32%. $1.48B. VTGN | Complete VistaGen Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
"Phase 3 topline results due in 2H 2023." This is one of three upcoming announcements for the company. VistaGen Therapeutics inched up $0.0018 (+1.29%) to $0.14 ...
Insiders who bought stock earlier this year lose -US$12k as VistaGen Therapeutics, Inc. (NASDAQ:VTGN) drops to US$34m. (Simply Wall St.) Sep-20-22 08:30AM. Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing …
What are individual investors saying about Vistagen Therapeutics? View the latest VTGN social media trends at MarketBeat. Skip to main content. S&P 500 4,594.63 (+0.59%) DOW 36,245.50 (+0.82%) ... Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat ...Nov 30, 2023 · The latest price target for Vistagen Therapeutics ( NASDAQ: VTGN) was reported by Stifel on Tuesday, November 14, 2023. The analyst firm set a price target for 12.00 expecting VTGN to rise to ... McCarthy covers the Healthcare sector, focusing on stocks such as VistaGen Therapeutics, Aprea Therapeutics, and Context Therapeutics. In another report released yesterday, H.C. Wainwright also ...Zinger Key Points. Small-cap stocks outperformed while tech stocks lagged Friday due to a surge in U.S. Treasury yields. Gold remained above $2,000/oz, indicating renewed investor optimism, while ...VistaGen Therapeutics (VTGN) In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on VistaGen Therapeutics, with a price target of $30.00. The company’s shares ...
Stock Information Historical Data Press ReleasesApple Inc. Common Stock. $191.6541 +1.9641 +1.04%. VistaGen Therapeutics, Inc. Common Stock (VTGN) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data ...According to 2 analysts, the average rating for VTGN stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 526.87% from the latest price.VistaGen Therapeutics (NASDAQ: VTGN) stock is falling hard on Friday after the clinical-stage biopharmaceutical company reported poor results from a Phase 3 study. That clinical trial covers PH94B ...Vistagen Therapeutics Inc. Real-Time Quotes. 3.66. BATS BZX Real-Time Price. As of 2:09pm ET. +0.28 / +8.28%. Today’s Change. 1.62. Today ||| 52-Week Range.Vistagen Therapeutics ( NASDAQ: VTGN) added ~17% on Tuesday after Stifel initiated its coverage with a Buy recommendation citing a potential blockbuster opportunity for its anxiety disorder drug ...
The current Vistagen Therapeutics [ VTGN] share price is $3.38. The Score for VTGN is 29, which is 42% below its historic median score of 50, and infers higher risk than normal. VTGN is currently trading in the 20-30% percentile range relative to …Feb 7, 2023 · Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 third quarter ended December 31, 2022.
Discover Vistagen Therapeutics' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. ... CEO & Director exercised options to buy US$120k worth of stock. May 17. VistaGen Announces Key Regulatory Update on Ph94b for the Acute Treatment of Social Anxiety …At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ...Stock Information Historical Data Press ReleasesStock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly …VistaGen Therapeutics, Inc. Common Stock (VTGN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets."Phase 3 topline results due in 2H 2023." This is one of three upcoming announcements for the company. VistaGen Therapeutics inched up $0.0018 (+1.29%) to $0.14 ...2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price.Shares of VistaGen Therapeutics ( VTGN 0.15%) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and ...SOUTH SAN FRANCISCO, Calif., August 07, 2023 -- ( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to …Nov 9, 2023 · MT. Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating. Oct. 17. MT. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.
See today’s best-performing stocks on TipRanks >> Based on VistaGen Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $179.6 ...
Vistagen Therapeutics Inc ( VTGN) is up 6.73% today. VTGN has an Overall Score of 56. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.12 and is up $0.21 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between …VistaGen Therapeutics, Inc. Common Stock (VTGN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Valuation metrics show that VistaGen Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ...What is Vistagen Therapeutics, Inc. (VTGN)'s stock price history? Over the last year, Vistagen Therapeutics, Inc.’s stock price has decreased by 7.38%. Vistagen Therapeutics, Inc. is currently ...Dec 1, 2023 · Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly Results; Section 16 Filings; Corporate Governance Executive Team; Board Committees; Documents & Charters Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the last patient has completed the study protocol in its Phase 2 clinical trial of PH94B for the treatment of …MT. Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating. Oct. 17. MT. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8.... therapeutics with the potential to be faster-acting, with fewer side effects ... Social anxiety nasal spray study results make Peninsula biotech's stock shoot up ...About VTGN. Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.Find the latest Earnings Report Date for VistaGen Therapeutics, Inc. Common Stock (VTGN) at Nasdaq.com.Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly …
The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...According to data from Benzinga Pro, VistaGen Therapeutics shares were up 17.6%, trading at $0.16 at the time of publication. The stock has a 52-week high of $1.79 and a 52-week low of $0.08.Insiders who bought stock earlier this year lose -US$12k as VistaGen Therapeutics, Inc. (NASDAQ:VTGN) drops to US$34m. (Simply Wall St.) Sep-20-22 08:30AM. Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit.Instagram:https://instagram. warren buffett in the newscheapest blue chip stocksbelize retirement coststocks lithium Aug 15, 2023 · 3.5900. +0.2400. +7.16%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 ... The second half of 2022 was always going to be a high-stakes moment for VistaGen Therapeutics as it awaited data from two phase 3 trials for a social anxiety disorder nasal spray. best stocks under 5arm's ipo Find the latest Institutional Holdings data for VistaGen Therapeutics, Inc. Common Stock ... Institutional Holdings information can be used to gauge the volatility and value on the company’s stock.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently … moneylion direct deposit reviews Vistagen Therapeutics Inc (NASDAQ:VTGN) stock is enjoying quite the boost today, after Stifel initiated coverage with a "buy" rating and $12 price target. Now, the only two analysts in coverage ...VistaGen Therapeutics (NASDAQ: VTGN) stock is falling hard on Friday after the clinical-stage biopharmaceutical company reported poor results from a Phase 3 study. That clinical trial covers PH94B ...VistaGen Therapeutics Stock Earnings. The value each VTGN share was expected to gain vs. the value that each VTGN share actually gained. VistaGen Therapeutics ( VTGN) reported Q3 2023 earnings per share (EPS) of -$0.66, beating estimates of -$0.68 by 3.53%. In the same quarter last year, VistaGen Therapeutics 's earnings per share (EPS) was …